Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2025-05-20 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from 华兰生物工程股份有限公司 regarding the completion of repurchase and cancellation of restricted shares under the 2023 restricted stock incentive plan. It details the number of shares repurchased, the price, the approval process, and the impact on share capital. The document is focused on the company's share repurchase and cancellation activities, including financial details related to the repurchase price and share capital changes. It is not a full financial report, audit report, or earnings release, but a specific announcement about share repurchase and capital change. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and content confirm it is not a mere announcement of a report but a substantive disclosure of the repurchase transaction.
2025-05-20 Chinese
关于参加河南辖区上市公司2025年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (437 characters) about the company's participation in an investor online reception day event. It includes details about the event date, time, and participants but does not contain any financial data, report content, or voting results. It is not a report itself but an announcement related to investor relations activities. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2025-05-16 Chinese
关于公司取得单采血浆许可证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (496 characters) about the company obtaining a single plasma collection license. It includes details about the license, effective dates, and the business impact. There is no financial data, no mention of a report being attached or published, and no regulatory form references. This fits the category of a general regulatory announcement about a business license acquisition, which does not fit into financial reports or other specific categories. Therefore, it is best classified as a Regulatory Filing (RNS).
2025-05-14 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2025 年第一季度报告' which translates to '2025 First Quarter Report'. It contains detailed financial data including income, net profit, cash flow, assets, liabilities, and equity for the quarter. It also includes shareholder information and detailed financial statements such as the consolidated balance sheet. The length of the document is substantial (15,000 characters), and it contains actual financial statements and substantive financial data for a period shorter than a full fiscal year (quarterly). Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-27 Chinese
华兰生物召开2024年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and proceedings of the 2024 Annual General Meeting (AGM) of 华兰生物工程股份有限公司. It details the qualifications of the meeting convener, attendees, proposals considered, voting procedures, and results of the shareholder meeting. The document focuses on the legality and validity of the AGM process and resolutions passed. It does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. The content is consistent with materials typically shared or issued in connection with an AGM, specifically legal opinions or materials related to the AGM process. Therefore, the document fits best under the category of AGM Information (AGM-R). The document length (5422 characters) and detailed content support it being a substantive AGM-related document rather than a brief announcement or regulatory filing.
2025-04-25 Chinese
华兰生物工程股份有限公司2024年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2024年度股东大会决议公告" which translates to "2024 Annual General Meeting Resolution Announcement." It details the date and method of the meeting, attendance, voting results on various proposals including the annual report, financial statements, profit distribution, auditor appointment, share repurchase, and amendments to the company charter. It also includes a legal opinion confirming the validity of the meeting and resolutions. The document is a formal announcement of the voting results and resolutions passed at the Annual General Meeting (AGM). It does not contain the full annual report or financial statements themselves but reports on the outcomes of the AGM. The length is about 4533 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-04-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.